Following the recent announcement from Penn Pharma on a new £14m high containment facility for production of tablets and capsules containing highly potent actives, the specialist provider of pharmaceutical development and manufacturing services, has today [19 April 2012] announced additional investment in its packing capacity and capabilities.
The established international pharma services company has installed a number of new packing lines and equipment to support an increased demand for packing and labelling a range of dosage types for both clinical and commercial needs. Penn has also re-modelled its existing facilities adding additional rooms for assembly of clinical trials kits, several new flexible secondary packing rooms and a new label production suite to further strengthen its European operation in Tredegar, South Wales.
Chief Executive, Dr Richard Yarwood, said: “We are pleased to be in a position to continue to invest in the existing operations whilst the new high containment unit is under construction. These new facilities have been designed to meet all current GMP requirements across our broad range of licences.
“This new equipment and expanded facilities will provide the business with the capacity to deliver larger contracts for clinical and commercial supplies including several projects recently won for EU commercial distribution.”
Penn has installed three additional labellers including one with capability to automatically label vials and ampoules. All the new labelling equipment features comprehensive security features including missing overprint presence detection sensors and pharmacode reading systems.
Penn’s clients can now benefit from the addition of three new tablet counters which have high speed infrared sensors for high accuracy counting of tablets and capsules including transparent soft gelatin capsules.
Blister packing capacity is being increased through the installation of a Klockner CP11 blister machine. The unit is capable of running up to 28 cycles per minute and is being modified to provide cold form capability. The new machine is extremely flexible and will provide short lead times for new pack formats.
Richard continued: “2012 is proving to be a year of rapid change and growth at Penn. We are pleased to be able expand our resources through these targeted investments at a time when the demand for our services continues to grow.”
For more information visit www.pennpharm.com
For more information contact:
Rhiannon Thompson|rhiannon.thompson@remarkablegroup.co.uk|+44 7554 014228|+44 1962 893 893
Emma Cox|emma.cox@remarkablegroup.co.uk|+44 1962 893 893
The Remarkable Group| Tel: +44 1962 893 893|Fax: +44 01962 893 889|The Pump House, Garnier Road, Winchester, Hampshire SO23 9QG
Penn Pharma is a privately owned provider of services to the pharmaceutical industry.
Penn Pharma’s services include Formulation Development and Analytical Services, support for clinical trial studies by manufacturing and labelling investigational materials for distribution to clinical sites worldwide.
Penn Pharma has specialist facilities for the supply of commercial licensed products including those requiring contained operations, protecting both operators and the environment.
Penn Pharma is inspected by many authorities allowing supply of services and products to the international market (e.g MHRA, FDA and ANVISA) for both human and veterinary medicines.